| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6664276 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(a month ago) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(20 days from now) | |
| US8722084 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(20 days from now) | |
|
US8722084 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(6 months from now) | |
|
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(6 months from now) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(2 years from now) | |
|
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(2 years from now) | |
| US7790755 | TAKEDA PHARMS USA | Controlled release preparation |
Aug, 2026
(2 years from now) | |
| US8105626 | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Sep, 2026
(3 years from now) | |
|
US7790755 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Feb, 2027
(3 years from now) | |
|
US8105626 (Pediatric) | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Mar, 2027
(3 years from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(4 years from now) | |
| US8173158 | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Mar, 2030
(6 years from now) | |
|
US8173158 (Pediatric) | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Sep, 2030
(6 years from now) | |
| US9233103 | TAKEDA PHARMS USA | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
Mar, 2032
(8 years from now) | |
Dexilant is owned by Takeda Pharms Usa.
Dexilant contains Dexlansoprazole.
Dexilant has a total of 18 drug patents out of which 2 drug patents have expired.
Expired drug patents of Dexilant are:
- US6664276*PED
- US6664276
Dexilant was authorised for market use on 30 January, 2009.
Dexilant is available in capsule, delayed release;oral dosage forms.
Dexilant can be used as use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions, for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (gerd); to maintain healing of ee and relief of heartburn; for healing of all grades of erosive esophagitis (ee), treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; healing of all grades of erosive esophagitis (ee) for up to 8 weeks; maintain healing of erosive esophagitis (ee) for up to 6 months, treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; to maintain healing of ee and relief of heartburn; maintain healing of erosive esophagitis (ee) for up to 6 months; healing of all grades of erosive esophagitis (ee) for up to 8 weeks.
The generics of Dexilant are possible to be released after 05 March, 2032.
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: For the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (gerd); To maintain healing of ee and relief of heartburn; For healing of all grades of erosive esophagi...
Dosage: CAPSULE, DELAYED RELEASE;ORAL
DEXILANT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic